Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
AceLink Therapeutics' oral GCS inhibitor AL01211 demonstrated 50% reduction in GL3 levels at 30mg daily dose, with higher reductions observed at 60mg in Phase 2 trial for classic male Fabry disease patients.
TechnoDerma Medicines reported positive Phase 2a results for topical TDM-180935 in Atopic Dermatitis, showing strong efficacy and minimal systemic exposure.